Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;2012:585170.
doi: 10.1155/2012/585170. Epub 2012 Oct 4.

Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction

D E Barre  1 , K A Mizier-Barre, E Stelmach, J Hobson, O Griscti, A Rudiuk, D Muthuthevar
Affiliations
Free PMC article

Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction

D E Barre et al. J Nutr Metab. .
Free PMC article
Favorites

Abstract

Aim. Animal and human study evidence supports the hypothesis that flaxseed lignan complex (FLC) at a dose of 600 mg secoisolariciresinol diglucoside (SDG)/day for three months would combat hyperglycaemia, dyslipidemia, blood pressure, central obesity, prothrombotic state, inflammation, and low density lipoprotein (LDL) oxidation. Methods. Sixteen type 2 diabetic patients completed this double-blind, randomised crossover placebo-controlled study. A univariate repeated measures analysis of covariance (significance P < 0.05) was followed by a mixed linear model effects analysis corrected for multiple comparisons (MCC). Results. Prior to MCC, FLC caused decreased fasting plasma glucose, A1c, inflammation (c-reactive protein (CRP) and interleukin-6 (IL-6)), and increased bleeding time. After correction for multiple comparisons, FLC induced a statistically significant increase in bleeding time and smaller waist circumference gain. No treatment effect occurred in the other variables before or after adjustment. Conclusions. It is concluded that FLC significantly increased bleeding time thus reducing the prothrombotic state, reduced central obesity gain as measured by waist circumference, and did not affect significantly the other dependent variables measured after adjustment for multiple comparisons. These findings, not yet published in human type 2 diabetes, suggest that this FLC dose over at least three months, may, subject to further investigation, reduce polypharmacy.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

References

    1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. - PubMed
    1. D’Souza A, Hussain M, Howarth FC, Woods NM, Bidasee K, Singh J. Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Molecular and Cellular Biochemistry. 2009;331(1-2):89–116. - PubMed
    1. Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clinical and Experimental Pharmacology and Physiology. 2008;35(4):434–437. - PubMed
    1. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology. 2006;47(6):1093–1100. - PubMed
    1. Canadian Diabetes Association Clinical Practice Guidelines. 2008. http://www.diabetes.ca/for-professionals/resources/2008-cpg.
Feedback